Centenial Surgical Suture Ltd
₹ 130
3.92%
25 Nov
- close price
About
Incorporated in 1995, Centenial Surgical Suture Ltd is engaged in manufacturing of surgical sutures & other medical devices.
Key Points
- Market Cap ₹ 47.4 Cr.
- Current Price ₹ 130
- High / Low ₹ 157 / 84.0
- Stock P/E 51.0
- Book Value ₹ 89.5
- Dividend Yield 0.00 %
- ROCE 8.07 %
- ROE 3.57 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.80% over past five years.
- Company has a low return on equity of 2.88% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
54.00 | 50.96 | 51.71 | 51.39 | 52.84 | 52.73 | 56.05 | 55.61 | 36.93 | 44.43 | 52.66 | 51.19 | 52.44 | |
49.15 | 46.39 | 46.47 | 46.71 | 47.95 | 48.26 | 50.64 | 49.68 | 31.82 | 39.94 | 48.26 | 46.04 | 46.29 | |
Operating Profit | 4.85 | 4.57 | 5.24 | 4.68 | 4.89 | 4.47 | 5.41 | 5.93 | 5.11 | 4.49 | 4.40 | 5.15 | 6.15 |
OPM % | 8.98% | 8.97% | 10.13% | 9.11% | 9.25% | 8.48% | 9.65% | 10.66% | 13.84% | 10.11% | 8.36% | 10.06% | 11.73% |
0.02 | 0.04 | 0.10 | 0.02 | 0.01 | 0.05 | 0.02 | 0.09 | 0.09 | 0.04 | 0.13 | 0.13 | 0.15 | |
Interest | 1.70 | 1.31 | 1.61 | 1.65 | 1.77 | 1.51 | 1.89 | 2.31 | 2.12 | 1.93 | 1.77 | 2.62 | 2.52 |
Depreciation | 0.58 | 0.59 | 0.83 | 0.68 | 0.59 | 0.60 | 0.69 | 1.55 | 1.55 | 1.53 | 1.30 | 1.39 | 2.65 |
Profit before tax | 2.59 | 2.71 | 2.90 | 2.37 | 2.54 | 2.41 | 2.85 | 2.16 | 1.53 | 1.07 | 1.46 | 1.27 | 1.13 |
Tax % | 39.38% | 33.95% | 34.14% | 34.18% | 32.68% | 36.10% | 29.12% | 39.81% | 37.25% | 42.06% | 39.73% | 11.02% | |
1.57 | 1.79 | 1.92 | 1.56 | 1.72 | 1.54 | 2.02 | 1.30 | 0.96 | 0.63 | 0.89 | 1.13 | 0.93 | |
EPS in Rs | 4.30 | 4.91 | 5.26 | 4.28 | 4.71 | 4.22 | 5.54 | 3.56 | 2.63 | 1.73 | 2.44 | 3.10 | 2.55 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -2% |
3 Years: | 12% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | -5% |
5 Years: | -11% |
3 Years: | 6% |
TTM: | -2% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 25% |
3 Years: | 36% |
1 Year: | 21% |
Return on Equity | |
---|---|
10 Years: | 5% |
5 Years: | 3% |
3 Years: | 3% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 | 5.42 |
Reserves | 12.04 | 13.83 | 15.79 | 17.35 | 19.07 | 20.62 | 22.63 | 23.18 | 24.15 | 24.77 | 25.66 | 26.79 | 27.22 |
12.65 | 11.32 | 12.28 | 13.11 | 15.24 | 14.37 | 13.10 | 12.72 | 13.47 | 9.30 | 9.92 | 23.24 | 0.00 | |
17.63 | 19.53 | 21.80 | 16.68 | 16.07 | 14.89 | 15.61 | 27.96 | 27.00 | 21.85 | 25.40 | 23.70 | 54.43 | |
Total Liabilities | 47.74 | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 87.07 |
4.72 | 4.53 | 4.13 | 3.64 | 3.71 | 3.80 | 4.08 | 10.44 | 8.97 | 7.60 | 6.46 | 12.77 | 20.77 | |
CWIP | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.22 | 0.22 | 0.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
42.83 | 45.38 | 50.97 | 48.73 | 51.90 | 51.28 | 52.46 | 58.62 | 61.07 | 53.74 | 59.94 | 66.38 | 66.30 | |
Total Assets | 47.74 | 50.10 | 55.29 | 52.56 | 55.80 | 55.30 | 56.76 | 69.28 | 70.04 | 61.34 | 66.40 | 79.15 | 87.07 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.63 | -0.25 | 0.21 | -1.51 | 0.00 | 1.76 | 1.55 | 2.08 | 1.97 | 4.75 | 1.30 | 6.21 | |
-0.53 | -0.42 | -0.36 | -0.19 | -2.38 | -0.64 | -1.02 | -1.31 | -0.89 | -0.17 | -0.18 | -7.92 | |
2.24 | -1.34 | 0.96 | 0.82 | 2.14 | -0.88 | -1.27 | -0.37 | -1.27 | -4.87 | -1.05 | 2.06 | |
Net Cash Flow | 2.34 | -2.01 | 0.80 | -0.88 | -0.25 | 0.24 | -0.75 | 0.40 | -0.18 | -0.28 | 0.07 | 0.35 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 127.89 | 135.08 | 138.21 | 132.75 | 130.76 | 125.29 | 134.80 | 153.26 | 221.39 | 160.44 | 142.71 | 134.05 |
Inventory Days | 218.51 | 297.67 | 350.07 | 365.93 | 468.59 | 465.89 | 434.68 | 483.86 | 1,276.44 | 599.23 | 677.26 | 909.72 |
Days Payable | 144.77 | 162.36 | 167.34 | 124.26 | 146.28 | 135.64 | 120.26 | 187.98 | 372.75 | 159.00 | 222.42 | 207.75 |
Cash Conversion Cycle | 201.63 | 270.39 | 320.94 | 374.42 | 453.06 | 455.54 | 449.22 | 449.14 | 1,125.08 | 600.67 | 597.56 | 836.02 |
Working Capital Days | 159.45 | 187.94 | 205.48 | 233.39 | 156.25 | 164.05 | 167.69 | 172.36 | 403.64 | 313.08 | 276.49 | 329.63 |
ROCE % | 15.21% | 13.25% | 14.08% | 11.59% | 11.40% | 9.78% | 11.62% | 10.84% | 8.65% | 7.27% | 8.03% | 8.07% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
- Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Nov
-
Standalone Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024
14 Nov - Approval of standalone un-audited financial results.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On November 14, 2024 Pursuant To Regulation 30 Of The SEBI (LODR [LODR]) Regulations, 2015.
14 Nov - Board approved standalone un-audited financial results for Q2 2024.
-
Board Meeting Intimation for Approval Of Standalone Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2024 As Per Regulation 33 Of The SEBI (LODR) Regulations, 2015
7 Nov - Board meeting for approval of financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
Company manufactures highly specialized absorbable and non-absorbable sutures (cardio vascular sutures and atraumatic needled sutures) that are primarily used in CABG surgeries, and other medical devices. It sells products under:
a) Absorbable Sutures:[1]
Consists of Natural Sutures with brand names like Centenial -Catgut Plain and Centenial-Catgut Chromic in addition to Synthetic Sutures, with brand names like Centicryl, Monosynth and Centisorb
b) Non Absorbable Sutures:[2]
Brand names like Centilene, Centlon Centisilk, Centlinen, Centibond, Centsteel, Centidene
c) Medical Devices:[3]
T-suit, Centilene Mesh, Skin Stapler, Centiclip, Aortic Punch and KNIFE which is a Cardiovascular Vessel Knife